Bio-Rad Laboratories (BIO) 151.66 $BIO Illumina
Post# of 273249
Posted On: 09/06/2016 5:16:48 PM
Bio-Rad Laboratories (BIO) 151.66 $BIO
Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell Genomics
BusinessWire - Wed Aug 10, 5:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data. Under the agreement FlowJo, LLC, the producer of FlowJo, market-leading software for single cell analysis, will develop a new software application. It will provide additional secondary and tertiary analysis and visualization of datasets with an intuitive approach built on 19 years of experience working with cell biologists and immunologists in single cell phenotyping. The application will seamlessly integrate with Illumina's Single Cell RNA BaseSpace app, and provide a solution accelerating discovery.
BIO: 151.66 (+0.52), ILMN: 170.18 (+2.28)
Look for Shares of Bio-Rad Laboratories to Potentially Pullback after Yesterday's 6.97% Rise
Comtex SmarTrend(R) - Thu Aug 04, 2:32PM CDT
Bio-Rad Laboratories (NYSE:BIO) traded in a range yesterday that spanned from a low of $144.99 to a high of $158.50. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $149.95 on volume of 211,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIO: 151.66 (+0.52)
Bio-Rad Reports Second-Quarter 2016 Financial Results
Marketwire Canada - Wed Aug 03, 3:18PM CDT
HERCULES, CA--(Marketwired - Aug 3, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2016.
BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 29.97 (+0.33), INSY: 14.93 (+0.30), CSII: 24.89 (+0.20), BIO: 151.66 (+0.52), CNAT: 1.82 (-0.02)
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Bio-Rad Laboratories, Inc.
ACCESSWIRE - Mon May 16, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Levi & Korsinsky announces it has commenced an investigation of Bio-Rad Laboratories, Inc. (NYSE: BIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/bio-rad-laboratories or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
BIO: 151.66 (+0.52)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Bio-Rad Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Mon May 16, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 151.66 (+0.52)
Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO. on Thursday reported first-quarter profit of $12.3 million.
BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 151.66 (+0.52), ILMN: 170.18 (+2.28), BIO.B: 151.40 (unch)
Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 8.66 (-0.14), BIO: 151.66 (+0.52), ILMN: 170.18 (+2.28), EXAC: 27.89 (-0.01)
Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 160.35 (+0.80), BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics
BusinessWire - Mon Jan 11, 1:31PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly and time-consuming process.
BIO: 151.66 (+0.52), ILMN: 170.18 (+2.28)
Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Illumina and FlowJo, LLC Partner to Develop and Co-Market a Software Solution for Single Cell Genomics
BusinessWire - Wed Aug 10, 5:30AM CDT
Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data. Under the agreement FlowJo, LLC, the producer of FlowJo, market-leading software for single cell analysis, will develop a new software application. It will provide additional secondary and tertiary analysis and visualization of datasets with an intuitive approach built on 19 years of experience working with cell biologists and immunologists in single cell phenotyping. The application will seamlessly integrate with Illumina's Single Cell RNA BaseSpace app, and provide a solution accelerating discovery.
BIO: 151.66 (+0.52), ILMN: 170.18 (+2.28)
Look for Shares of Bio-Rad Laboratories to Potentially Pullback after Yesterday's 6.97% Rise
Comtex SmarTrend(R) - Thu Aug 04, 2:32PM CDT
Bio-Rad Laboratories (NYSE:BIO) traded in a range yesterday that spanned from a low of $144.99 to a high of $158.50. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $149.95 on volume of 211,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIO: 151.66 (+0.52)
Bio-Rad Reports Second-Quarter 2016 Financial Results
Marketwire Canada - Wed Aug 03, 3:18PM CDT
HERCULES, CA--(Marketwired - Aug 3, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2016. BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 29.97 (+0.33), INSY: 14.93 (+0.30), CSII: 24.89 (+0.20), BIO: 151.66 (+0.52), CNAT: 1.82 (-0.02)
Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA). BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Bio-Rad Laboratories, Inc.
ACCESSWIRE - Mon May 16, 2:25PM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Levi & Korsinsky announces it has commenced an investigation of Bio-Rad Laboratories, Inc. (NYSE: BIO) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to: http://zlk.9nl.com/bio-rad-laboratories or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
BIO: 151.66 (+0.52)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Bio-Rad Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
ACCESSWIRE - Mon May 16, 9:08AM CDT
NEW YORK, NY / ACCESSWIRE / May 16, 2016 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 151.66 (+0.52)
Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO.
on Thursday reported first-quarter profit of $12.3 million. BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016. BIO: 151.66 (+0.52), ILMN: 170.18 (+2.28), BIO.B: 151.40 (unch)
Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year. BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 8.66 (-0.14), BIO: 151.66 (+0.52), ILMN: 170.18 (+2.28), EXAC: 27.89 (-0.01)
Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety. IBM: 160.35 (+0.80), BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics
BusinessWire - Mon Jan 11, 1:31PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc. (NASDAQ: ILMN) today announced an exclusive partnership to develop the most comprehensive next-generation sequencing (NGS) workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly and time-consuming process.
BIO: 151.66 (+0.52), ILMN: 170.18 (+2.28)
Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators." BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors. BIO: 151.66 (+0.52), BIO.B: 151.40 (unch)
(0)
(0)Scroll down for more posts ▼